OncUView.tv - Video Library - Oncology News and Information for Healthcare Professionals > Phase 3 AXIS 1032 Trial Discussion with Brian I. Rini, MD - Comparing axitinib to sorafenib in patients with previously-treated advanced RCC

Install latest flash player if this video gallery doesn't work.

Phase 3 AXIS 1032 Trial Discussion with Brian I. Rini, MD - Comparing axitinib to sorafenib in patients with previously-treated advanced RCC
AXIS 1032 is a pivotal Phase 3 clinical trial comparing axitinib to sorafenib in patients with previously-treated advanced renal cell carcinoma (RCC). Axitinib significantly extended progression-free survival (PFS) [HR=0.665, 95% CI; P<0.0001], with a median PFS of 6.7 months (95% CI, 6.3-8.6), compared with 4.7 months (4.6-5.6) for those treated with sorafenib, a standard of care for this patient population.